Immunovant Inc (IMVT) concluded trading on Wednesday at a closing price of $16.42, with 3.71 million shares of worth about $60.95 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -42.41% during that period and on April 03, 2025 the price saw a gain of about 8.03%. Currently the company’s common shares owned by public are about 147.20M shares, out of which, 69.37M shares are available for trading.
Stock saw a price change of -8.22% in past 5 days and over the past one month there was a price change of -11.20%. Year-to-date (YTD), IMVT shares are showing a performance of -33.71% which decreased to -48.05% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $15.00 but also hit the highest price of $34.47 during that period. The average intraday trading volume for Immunovant Inc shares is 1.53 million. The stock is currently trading -12.49% below its 20-day simple moving average (SMA20), while that difference is down -17.83% for SMA50 and it goes to -37.52% lower than SMA200.
Immunovant Inc (NASDAQ: IMVT) currently have 147.20M outstanding shares and institutions hold larger chunk of about 49.43% of that.
The stock has a current market capitalization of $2.79B and its 3Y-monthly beta is at 0.75. It has posted earnings per share of -$2.62 in the same period. It has Quick Ratio of 6.04 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IMVT, volatility over the week remained 8.40% while standing at 7.00% over the month.
Stock’s fiscal year EPS is expected to drop by -49.95% while it is estimated to decrease by -8.41% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on March 03, 2025 offering a Hold rating for the stock and assigned a target price of $20 to it. On October 10, 2024, Raymond James Resumed their recommendations, while on October 09, 2024, Oppenheimer Reiterated their ratings for the stock with a price target of $53. Stock get an Outperform rating from Oppenheimer on March 28, 2024.
